Gayle S. Jameson
Translational Genomics Research Institute
What is this?
Publications 74
#1Erkut BorazanciH-Index: 8
#2Ronald L. KornH-Index: 14
Last. Gayle S. JamesonH-Index: 12
view all 10 authors...
#1Gayle S. Jameson (TGen: Translational Genomics Research Institute)H-Index: 12
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
view all 16 authors...
Importance Genomes of metastatic pancreatic cancers frequently contain intrachromosomal aberrations, indicating a DNA repair deficiency associated with sensitivity to DNA damaging agents, such as platinum. Objective To determine response rate following treatment with nab-paclitaxel plus gemcitabine plus platinum-based cisplatin for patients with metastatic pancreatic ductal adenocarcinoma (PDA). Design, Setting, and Participants This was a single-arm, open-label, phase 1b/2 clinical trial of nab...
1 CitationsSource
#1Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
#2Gayle S. Jameson (TGen: Translational Genomics Research Institute)H-Index: 12
view all 16 authors...
Background: Localized PDAC management has recently evolved. Due to concerns over micrometastases at diagnosis, the use of neoadjuvant chemotherapy for PDAC has become more common. Typical therapies involve the use of multiagent systemic chemotherapy with or without radiation therapy. Cancer antigen 19-9 (CA 19-9) normalization in borderline resectable (BR) and locally advanced (LA) PDAC has been associated with greater OS. The addition of cisplatin (C) to gemcitabine (G) and paclitaxel protein b...
#1Sarah K. Highlander (TGen: Translational Genomics Research Institute)
#2Vincent Chung (City of Hope National Medical Center)H-Index: 15
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
view all 8 authors...
Background: Pancreatic cancer remains a deadly disease, and immunotherapy is effective in only 1-2% of microsatellite instability-high pancreatic cancers. The response to immunotherapy is very heterogeneous across tumor types, but recently there is evidence that the gastrointestinal microbiome may influence the response to immunotherapy. The SU2C Catalyst Trial is a randomized phase II maintenance trial to compare outcomes using a combination regimen of the vitamin D agonist, paricalcitol, plus ...
#2Rolf HultschH-Index: 1
Last. Erkut BorazanciH-Index: 8
view all 6 authors...
Background: Thrombocytopenia may be a concern in treating pancreatic ductal adenocarcinomas (PDAC). Due to anatomic position these tumors commonly cause narrowing or occlusion of the splenic vein which may lead to hypersplenism and thrombocytopenia due to sequestration. PDAC patients with thrombocytopenia have limited options for treatment. Partial splenic embolization (PSE) is a procedure developed as an alternative to splenectomy in individuals with hypersplenism. The purpose of our study was ...
#1Gayle S. JamesonH-Index: 12
#2Erkut BorazanciH-Index: 8
Last. Daniel D. Von HoffH-Index: 84
view all 7 authors...
#1Erkut BorazanciH-Index: 8
#2Gayle S. JamesonH-Index: 12
Last. Daniel D. Von HoffH-Index: 84
view all 9 authors...
#1Muhammad Shaalan Beg (UTSW: University of Texas Southwestern Medical Center)H-Index: 13
#2Andrew M. Lowy (UCSD: University of California, San Diego)H-Index: 50
Last. Rolf A. BrekkenH-Index: 14
view all 15 authors...
TPS473Background: The Axl pathway coordinately mediates immune evasion and drug resistance in pancreatic cancer. Systemic Axl inhibition can enhance the efficacy of cancer therapy by blocking tumor...
#1Andreas SeeberH-Index: 9
#2Georges ChahineH-Index: 7
Last. Heinz ZwierzinaH-Index: 1
view all 9 authors...
1 CitationsSource
#1Li-Tzong Chen (NCKU: National Cheng Kung University)H-Index: 37
#2Jens T. Siveke (DKFZ: German Cancer Research Center)H-Index: 26
Last. Richard A HubnerH-Index: 21
view all 19 authors...
Background: In the phase 3 randomised NAPOLI-1 clinical study, a 45% increase in median overall survival (OS) was shown with liposomal irinotecan, 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) versus 5-FU/LV in patients with metastatic pancreatic cancer progressing after gemcitabine-based therapy. Here, we report data from a pre-specified, expanded analysis of outcomes in the per-protocol (PP) population. Materials and methods: The PP population comprised patients receiving >80% of planned tre...
3 CitationsSource